Literature DB >> 23801630

MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma.

Cuiling Liu1, Javeed Iqbal, Julie Teruya-Feldstein, Yulei Shen, Magdalena Julia Dabrowska, Karen Dybkaer, Megan S Lim, Roberto Piva, Antonella Barreca, Elisa Pellegrino, Elisa Spaccarotella, Cynthia M Lachel, Can Kucuk, Chun-Sun Jiang, Xiaozhou Hu, Sharathkumar Bhagavathi, Timothy C Greiner, Dennis D Weisenburger, Patricia Aoun, Sherrie L Perkins, Timothy W McKeithan, Giorgio Inghirami, Wing C Chan.   

Abstract

Anaplastic large-cell lymphomas (ALCLs) encompass at least 2 systemic diseases distinguished by the presence or absence of anaplastic lymphoma kinase (ALK) expression. We performed genome-wide microRNA (miRNA) profiling on 33 ALK-positive (ALK[+]) ALCLs, 25 ALK-negative (ALK[-]) ALCLs, 9 angioimmunoblastic T-cell lymphomas, 11 peripheral T-cell lymphomas not otherwise specified (PTCLNOS), and normal T cells, and demonstrated that ALCLs express many of the miRNAs that are highly expressed in normal T cells with the prominent exception of miR-146a. Unsupervised hierarchical clustering demonstrated distinct clustering of ALCL, PTCL-NOS, and the AITL subtype of PTCL. Cases of ALK(+) ALCL and ALK(-) ALCL were interspersed in unsupervised analysis, suggesting a close relationship at the molecular level. We identified an miRNA signature of 7 miRNAs (5 upregulated: miR-512-3p, miR-886-5p, miR-886-3p, miR-708, miR-135b; 2 downregulated: miR-146a, miR-155) significantly associated with ALK(+) ALCL cases. In addition, we derived an 11-miRNA signature (4 upregulated: miR-210, miR-197, miR-191, miR-512-3p; 7 downregulated: miR-451, miR-146a, miR-22, miR-455-3p, miR-455-5p, miR-143, miR-494) that differentiates ALK(-) ALCL from other PTCLs. Our in vitro studies identified a set of 32 miRNAs associated with ALK expression. Of these, the miR-17∼92 cluster and its paralogues were also highly expressed in ALK(+) ALCL and may represent important downstream effectors of the ALK oncogenic pathway.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23801630      PMCID: PMC3778551          DOI: 10.1182/blood-2012-08-447375

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.

Authors:  Roberto Piva; Elisa Pellegrino; Michela Mattioli; Luca Agnelli; Luigia Lombardi; Francesco Boccalatte; Giulia Costa; Bruce A Ruggeri; Mangeng Cheng; Roberto Chiarle; Giorgio Palestro; Antonino Neri; Giorgio Inghirami
Journal:  J Clin Invest       Date:  2006-11-16       Impact factor: 14.808

2.  Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR.

Authors:  Stella Maris Ranuncolo; Jose M Polo; Jamil Dierov; Michael Singer; Tracy Kuo; John Greally; Roland Green; Martin Carroll; Ari Melnick
Journal:  Nat Immunol       Date:  2007-06-10       Impact factor: 25.606

3.  Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets.

Authors:  Pier Paolo Piccaluga; Claudio Agostinelli; Andrea Califano; Maura Rossi; Katia Basso; Simonetta Zupo; Philip Went; Ulf Klein; Pier Luigi Zinzani; Michele Baccarani; Riccardo Dalla Favera; Stefano A Pileri
Journal:  J Clin Invest       Date:  2007-02-15       Impact factor: 14.808

4.  Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling.

Authors:  Kai Fu; Dennis D Weisenburger; Timothy C Greiner; Sandeep Dave; George Wright; Andreas Rosenwald; Michael Chiorazzi; Javeed Iqbal; Stefan Gesk; Reiner Siebert; Daphne De Jong; Elaine S Jaffe; Wyndham H Wilson; Jan Delabie; German Ott; Bhavana J Dave; Warren G Sanger; Lynette M Smith; Lisa Rimsza; Rita M Braziel; H Konrad Müller-Hermelink; Elias Campo; Randy D Gascoyne; Louis M Staudt; Wing C Chan
Journal:  Blood       Date:  2005-08-25       Impact factor: 22.113

5.  A microRNA polycistron as a potential human oncogene.

Authors:  Lin He; J Michael Thomson; Michael T Hemann; Eva Hernando-Monge; David Mu; Summer Goodson; Scott Powers; Carlos Cordon-Cardo; Scott W Lowe; Gregory J Hannon; Scott M Hammond
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

6.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

7.  Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas.

Authors:  Mary Ann Thompson; Jennifer Stumph; Sarah E Henrickson; Andreas Rosenwald; Qifu Wang; Sandy Olson; Stephen J Brandt; Jeremy Roberts; Xueqiong Zhang; Yu Shyr; Marsha C Kinney
Journal:  Hum Pathol       Date:  2005-05       Impact factor: 3.466

8.  Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules.

Authors:  H D Foss; I Anagnostopoulos; I Araujo; C Assaf; G Demel; J A Kummer; M Hummel; H Stein
Journal:  Blood       Date:  1996-11-15       Impact factor: 22.113

9.  Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes.

Authors:  Laurence Lamant; Aurélien de Reyniès; Marie-Michèle Duplantier; David S Rickman; Frédérique Sabourdy; Sylvie Giuriato; Laurence Brugières; Philippe Gaulard; Estelle Espinos; Georges Delsol
Journal:  Blood       Date:  2006-10-31       Impact factor: 22.113

10.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728

View more
  44 in total

1.  Alterations of microRNA and microRNA-regulated messenger RNA expression in germinal center B-cell lymphomas determined by integrative sequencing analysis.

Authors:  Kebria Hezaveh; Andreas Kloetgen; Stephan H Bernhart; Kunal Das Mahapatra; Dido Lenze; Julia Richter; Andrea Haake; Anke K Bergmann; Benedikt Brors; Birgit Burkhardt; Alexander Claviez; Hans G Drexler; Roland Eils; Siegfried Haas; Steve Hoffmann; Dennis Karsch; Wolfram Klapper; Kortine Kleinheinz; Jan Korbel; Helene Kretzmer; Markus Kreuz; Ralf Küppers; Chris Lawerenz; Ellen Leich; Markus Loeffler; Luisa Mantovani-Loeffler; Cristina López; Alice C McHardy; Peter Möller; Marius Rohde; Philip Rosenstiel; Andreas Rosenwald; Markus Schilhabel; Matthias Schlesner; Ingrid Scholz; Peter F Stadler; Stephan Stilgenbauer; Stéphanie Sungalee; Monika Szczepanowski; Lorenz Trümper; Marc A Weniger; Reiner Siebert; Arndt Borkhardt; Michael Hummel; Jessica I Hoell
Journal:  Haematologica       Date:  2016-07-06       Impact factor: 9.941

2.  STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma.

Authors:  Elisa Spaccarotella; Elisa Pellegrino; Manuela Ferracin; Cristina Ferreri; Giuditta Cuccuru; Cuiling Liu; Javeed Iqbal; Daniela Cantarella; Riccardo Taulli; Paolo Provero; Ferdinando Di Cunto; Enzo Medico; Massimo Negrini; Wing C Chan; Giorgio Inghirami; Roberto Piva
Journal:  Haematologica       Date:  2013-08-23       Impact factor: 9.941

Review 3.  Dysregulation of microRNAs and their association in the pathogenesis of T-cell lymphoma/leukemias.

Authors:  Sho Ikeda; Hiroyuki Tagawa
Journal:  Int J Hematol       Date:  2014-02-25       Impact factor: 2.490

Review 4.  Peripheral T cell lymphoma in Asia.

Authors:  Sanghui Park; Young Hyeh Ko
Journal:  Int J Hematol       Date:  2014-01-31       Impact factor: 2.490

5.  MicroRNA expression profiling and DNA methylation signature for deregulated microRNA in cutaneous T-cell lymphoma.

Authors:  Juan Sandoval; Angel Díaz-Lagares; Rocío Salgado; Octavio Servitje; Fina Climent; Pablo L Ortiz-Romero; Amparo Pérez-Ferriols; Maria P Garcia-Muret; Teresa Estrach; Mar Garcia; Lara Nonell; Manel Esteller; Ramon M Pujol; Blanca Espinet; Fernando Gallardo
Journal:  J Invest Dermatol       Date:  2014-11-18       Impact factor: 8.551

6.  Genetics of anaplastic large cell lymphoma.

Authors:  Yu Zeng; Andrew L Feldman
Journal:  Leuk Lymphoma       Date:  2015-07-21

7.  IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma.

Authors:  Nina Prokoph; Nicola A Probst; Liam C Lee; Jack M Monahan; Jamie D Matthews; Huan-Chang Liang; Klaas Bahnsen; Ivonne A Montes-Mojarro; Elif Karaca-Atabay; Geeta G Sharma; Vikas Malik; Hugo Larose; Sorcha D Forde; Stephen P Ducray; Cosimo Lobello; Qi Wang; Shi-Lu Luan; Šárka Pospíšilová; Carlo Gambacorti-Passerini; G A Amos Burke; Shahid Pervez; Andishe Attarbaschi; Andrea Janíková; Hélène Pacquement; Judith Landman-Parker; Anne Lambilliotte; Gudrun Schleiermacher; Wolfram Klapper; Ralf Jauch; Wilhelm Woessmann; Gilles Vassal; Lukas Kenner; Olaf Merkel; Luca Mologni; Roberto Chiarle; Laurence Brugières; Birgit Geoerger; Isaia Barbieri; Suzanne D Turner
Journal:  Blood       Date:  2020-10-01       Impact factor: 22.113

Review 8.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

9.  Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.

Authors:  Coralie Hoareau-Aveilla; Thibaud Valentin; Camille Daugrois; Cathy Quelen; Géraldine Mitou; Samuel Quentin; Jinsong Jia; Salvatore Spicuglia; Pierre Ferrier; Monica Ceccon; Sylvie Giuriato; Carlo Gambacorti-Passerini; Pierre Brousset; Laurence Lamant; Fabienne Meggetto
Journal:  J Clin Invest       Date:  2015-08-10       Impact factor: 14.808

Review 10.  Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.

Authors:  Ruifang Sun; L Jeffrey Medeiros; Ken H Young
Journal:  Mod Pathol       Date:  2016-08-01       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.